{"news_desk": "Business", "print_page": "2", "section_name": "Business Day", "subsection_name": null, "byline": {"contributor": "", "original": "By REUTERS", "person": [], "organization": "REUTERS"}, "abstract": "Merck & Company announces Food and Drug Administration plans to retract designation of Merck's combination treatment for hepatitis C as 'breakthrough therapy'; decision could delay approval of product for several months.", "type_of_material": "Brief", "word_count": "89", "lead_paragraph": "The company said regulators intended to rescind the \u201cbreakthrough therapy\u201d designation for its treatment because other new drugs were available.", "pub_date": "2015-02-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Merck Expects Delay for a Hepatitis C Therapy", "content_kicker": "Business Briefing", "print_headline": "Merck Expects Delay for a Hepatitis C Therapy"}, "snippet": "The company said regulators intended to rescind the \u201cbreakthrough therapy\u201d designation for its treatment because other new drugs were available.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/02/05/business/merck-expects-delay-for-a-hepatitis-c-therapy.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Merck & Company Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Hepatitis", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "4", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}], "blog": [], "_id": "54d2b8fa38f0d81f788a1ef0", "source": "The New York Times"}